MD, MPH, PhD student - Vascular medicine specialist / CCU-AH @HopSaintAntoine / Clinical epidemiology @Sorbonne_Univ_ / EAS Young Fellow @society_eas
Paris, France
Joined June 2017
- Tweets122
- Following292
- Followers144
- Likes546
Alexis F. Guédon retweeted
Does tocilizumab lower cardiovascular risk in giant cell arteritis? New observational data presented at #ESCCongress + sim pub: target trial emulation of 1,997 pts found 2-yr MACE 6.4% vs 10.7% with methotrexate. ahajrnls.org/4gYfeTM @alguedon
Alexis F. Guédon retweeted
🦴 Giant cell arteritis & Clonal hematopoiesis (CH) —somatic mutations in HSCs
👥 55.1% of patients with GCA had CH
🔬 TET2 & JAK2 mutations in #GCA ➡️ Relapse & poor outcomes.
👉 Screening for CH may guide tailored therapies.
🔓rmdopen.bmj.com/content/10/4…
@alguedon
Alexis F. Guédon retweeted
Colchicine is the first anti-inflammatory drug approved for athero-CVD prevention
#CONVINCE tested colchicine in ischemic stroke🧠
The results were presented at #ESOC2024 by Peter Kelly @ESOstroke
ucd.ie/medicine/news/2024/co…
The primary endpoint was negative. A🧵with some thoughts
Alexis F. Guédon retweeted
🚨Anticoagulation for stroke prevention in AF and Treatment of VTE and Portal Vein Thrombosis in Cirrhosis: Guidance @ISTH
👏Congrats @GattAlexander @VirginiaHdezGea @CukerMd @DebSiegal @SimonStanworth @LaraNRoberts1
🙏Honored to have been a part of this
sciencedirect.com/science/ar…
Alexis F. Guédon retweeted
I had such a great time at the #EASCongress! Thanks to the #EASYoungFellows programme I was able to gain so many new experiences and expand my network. Hope to see you all again soon and thanks to everyone who made it such a fabulous congress! #EASCongress2024 #MyEAS2024 #EAS
Alexis F. Guédon retweeted
3 papers in NEJM published simultaneously with presentations by Christie Ballantyne and Bob Rosenson at the European Atherosclerosis Society Congress in Lyon France - documenting huge reductions in remnant cholesterol after siRNA inhibition of ApoC3 and ANGTPL3
Alexis F. Guédon retweeted
Also wanted to add, here is the free share link for anyone who needs access:
authors.elsevier.com/a/1j8O4…
Excited to see our @nih_nhlbi @NIH_NIAMS @MayoCancerCare collaboration looking at #VTE in #VEXAS syndrome out in this issue of @BloodJournal! Over 40% of patients had a VTE. @Yael_Kusne @AtefehGho @bhavishap29 ashpublications.org/blood/ar…
Alexis F. Guédon retweeted
Check out the commentary on our #VEXAS article in @BloodJournal
VEXAS syndrome: from a vascular perspective
ow.ly/CzUK50RTI1m #thrombosisandhemostasis
Alexis F. Guédon retweeted
Presented at #ERA24:
FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. nej.md/44U3slP
ALT Graphs showing the first major kidney disease event
Alexis F. Guédon retweeted
The multi societal #PAD guideline in print at long last… Amazing things can happen when specialties work together, review the evidence, and put the patient at the center. Hats off to a most collaborative writing committee. @herbaronowMD @DartmthSurgHSR @schuyler_jones
🆕 2024 ACC/AHA/Multisociety Guideline for the Management of Lower
Extremity PAD provides recommendations to guide clinicians in the Tx of patients with lower extremity PAD across its multiple clinical presentation subsets. bit.ly/3K0ypes
#JACC #cvPAD @heatherlgornik
Alexis F. Guédon retweeted
1/ Published today: The updated evidence-based recommendations for managing Lower Extremity PAD, originally outlined in the 2016 Guideline, now incorporate the latest research findings to assist clinicians.
✍🏽:@heatherlgornik
📖: @CircAHA
Alexis F. Guédon retweeted
3⃣rd edition of the 4EU+PharmacoEpi course with #PharmacoEpi students from all over Europe at @UniHeidelberg ! Great discussion on multi-database studies. Stay tuned for next edition in Jan 2025 ! @4EUplusAlliance
sante.sorbonne-universite.fr…
Alexis F. Guédon retweeted
📰 Our review is online @ThrombosisRese1 discussing risk factors during the acute phase of DVT that are associated with the development of PTS ⚡️🦵
👏Bravo @lina_2411 !
@PlanquetteSante @DavidMSmadja @GoudotG @SanchezOlivie11 @MedVasc_HEGP
@INNOVTE1
thrombosisresearch.com/artic…
Alexis F. Guédon retweeted
The 3rd edition of the 4EU+PharmacoEpi course has just started with 22 students from 5 EU universities ! A new extended edition supporting an integrative educational 🇪🇺 program in pharmacoepidemiology in the @4EUplusAlliance
Alexis F. Guédon retweeted
👏This state-of-the-art review from #isth2023 summarizes the role of #platelets in ischemic #stroke, as example of thrombo-inflammation, and cerebral venous #thrombosis, which is an immunothrombotic disease.
Fantastic work from @stegnerlab!
rpthjournal.org/article/S247…
Alexis F. Guédon retweeted
An editorial was just published on our article "Arterial stiffness tested by pulse wave velocity and augmentation index for #cardiovascular risk stratification in #antiphospholipid syndrome"
academic.oup.com/rheumatolog…
Alexis F. Guédon retweeted
#DOACs demonstrate comparable efficacy but exhibit different safety profiles. #Apixaban may confer an antithrombotic benefit w/out an ⬆️ risk for bleeding, distinguishing it from other contemporary anticoagulation strategies in pts w/ active cancer & #VTE bit.ly/3ShUbzo #JACCCardioOnc #cvCoag
Alexis F. Guédon retweeted
From the current issue: Primary results of the SAVAL randomized trial.
buff.ly/3tHlVUo
#CLTI #PeripheralArteryDisease #VascularTwitter
Alexis F. Guédon retweeted
Les #Pharmaciens d’Officine de Twitter/X 📲 I Need You ! 🙋🏻♂️🚺💊🩸
Faisable depuis votre smartphone <5min ⤵️⤵️⤵️
Cher Réseau, merci de diffuser
➡ Dans le cadre d'une Thèse à la Faculté de Pharmacie @univ_paris_cite nous réalisons une enquête auprès des Pharmaciens (<5 min⏱️) au sujet des patientes sous anticoagulant à l'officine avec saignement gynécologique 🚺💊🩸
forms.gle/GMSXvz5a9ewv85S96
